RxDoctor Payments Data

Joseph Diconcetto, MD

Allergy & Immunology · Bethlehem, PANPI 1679552418

Payments from drug & device makers

$3,420in general payments, 2019–2025

Across 73 payments — averaging $46.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Sanofi$693
  • Regeneron Healthcare Solutions, Inc.$406
  • GSK$311
  • CSL Behring$223
  • Amgen$180
  • plus $604 from 7 others

What the payments were for

  • Food & beverage$3,17193%
  • Education$2497%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,420 in reported general payments places this provider in the 50th percentile of 175 allergy & immunology providers in Pennsylvania.

See all allergy & immunology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$76,773
Medicare patients
146
Services billed
3,436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab18$41,476
Breo ElliptaFluticasone/Vilanterol30$22,178
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$20,334
Montelukast Sodium201$3,315
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$2,806
Epinephrine14$2,437
Azelastine Hcl71$2,095
Fluticasone Propionate88$1,791
Albuterol Sulfate HfaAlbuterol Sulfate55$1,630
Ipratropium Bromide21$1,162
Levocetirizine Dihydrochloride48$1,149
Ventolin HfaAlbuterol Sulfate14$1,118
Desloratadine13$998
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$744
Famotidine18$321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Trelegy Ellipta$311$42,51262 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 175 allergy & immunology providers in Pennsylvania.

Other allergy & immunology in Bethlehem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →